Trump Administration Pharmaceutical Pricing Agreements Face Implementation Questions

The Trump administration's most favored nation (MFN) pricing agreements with pharmaceutical manufacturers remain under scrutiny as implementation details emerge. These agreements aim to tie U.S. drug prices to lower international reference prices. Medicaid managed care organizations may see indirect effects through pharmacy benefit design and supplemental rebate negotiations, though the agreements primarily target Medicare Part B and Part D. The timing and scope of implementation remain uncertain, creating planning challenges for health plans managing pharmacy benefits across multiple programs.

Pharmacy · Managed Care